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ABSTRACT
The purpose of this independent study is to review the viral and
immunologic factors in human immunodeficiency virus (HIV) infection and
present the clinical manifestations most commonly associated with acquired
immune deficiency syndrome (AIDS). As physical therapists, we will thus
increase our knowledge base of this complex disease and understand the many
opportunistic infections associated with HIV infection and the various aspects of
AIDS. In addition, by having a better understanding of the disease, we may
overcome our fears, improve our personal attitudes toward patients with
HIV/AIDS, and improve and prolong the quality of life of individuals with the
disease.
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CHAPTER I
INTRODUCTION AND METHODOLOGY
No disease in modern time has had quite the impact on the civilized
world as had acquired immunodeficiency syndrome (AIDS). In January 1992,
the Centers for Disease Control (CDC) reported over one million Americans
infected with the human immunodeficiency syndrome (HIV), 206,392 diagnosed
with AIDS, and 133,232 having died from the disease. 1 AIDS is already a
leading killer of men and women 15 to 44 years old in our country.2 The scope
of the HIV/AIDS pandemic is even more dramatic world wide. The World
Health Organization (WHO) has estimated cumulative global total of HIVinfected adults and children as of 30 June 1993 is about 13 million, which
means that, for the world population, one in every 250 adults has been infected
with HIV.3 WHO estimates that over 2.5 million cumulative AIDS cases have
occurred to date, whereas over 50% of reported AIDS cases are from
developed countries, about 80% of all estimated AIDS cases are from the
developing world. 4 Although the outlook in the near future is promising for
curative treatment or effective vaccine, the National Commission of AIDS states
"even if a cure were found tomorrow the sequelae of the disease would still
affect our communities for 10 to 15 more years. ,,5

1

2

Amid the social and political upheaval precipitated by the HIV/AIDS
pandemic, a critical problem has silently but steadily emerged: Who is to
provide care for the increasing numbers of afflicted individuals? There is a
demanding need for more professionals to become active in both prevention
and treatment of the HIV disease. Although few practitioners have denied their
responsibility to provide care, there is a reluctance on the part of some to
actively participate. Caring for those with HIV infection entails a risk. There is
little doubt that the consequences of contracting AIDS are very grave, and it
understandable that health care workers, physical therapist among them, may
experience intense anxiety and fear.
The purpose of this independent study is to review the biology and
epidemiology of HIV infection and the most common clinical manifestations of
the virus. The study will allow the physical therapist an opportunity to
understand the disease process and make an important contribution to people
with HIV in all disease stages--acute, chronic, and terminal.
The methodology employed a review of existing literature, beginning with
a Med-lin computer search. Other sources reviewed included textbook
materials, government reports, and a personal interview with an HIV/AIDS
individual.

CHAPTER II
HISTORY AND EPIDEMIOLOGY
Although misunderstanding, fear, and discrimination still surround HIV
and AIDS, much has been learned. The earliest known case of death from
AIDS occurred in 1959.6 A paper published in Lancet, 1990, states the human
immunodeficiency virus was found in the tissues of a 25-year-old seaman from
northwestern part of Manchester, England who died of pneumonia in 1959. 6
The seaman's wife and three youngest daughters appear to also have been
infected, as they died of similar symptoms some years later. Other early cases
of HIV infection were in three members of a Norwegian family who developed
AIDS in the 1960s and died in 1976.6 Antibodies to the virus were found in the
blood of an individual from Zaire, Africa also in 1959, but it is not known if the
patient died from AIDS. 6 From analysis of the infection rates in Africa, it is
thought that HIV has existed in Africa for 30 to 40 years.6
The most prominent theory of how the virus started follows. In the 1950s
American doctors were testing a vaccine intended to wipe out the polio virus;
the vaccine was contaminated by the simian immunodeficiency virus (SIV).?
The contaminated polio vaccine was administered to at least 325,000 Central
Africans; it is hypothesized that after a series of mutations in humans, the virus
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established itself into its present deadly form.? The SIV is from a family of
relatively harmless primate retroviruses that is endemic in green monkeys of
equatorial Africa and closely related to the AIDS virus. 8
The epidemiology of HIV has become clearer and has been discussed by
a number of authorities in the United States. The Center for Disease Control
(CDC) has led the epidemiological investigation of AIDS. The disease that
became known as acquired immunodeficiency syndrome (AIDS) was first
reported in a 1981 Morbidity and Mortality Weekly Report, published by the
CDC. 9 In 1983, scientists working at the Pasteur Institute, Paris, isolated a
retrovirus from the lymph node of person with AIDS-related symptoms. 10 In
1985, epidemiologic and virologic studies confirmed a ribonucleicacid (RNA)
retrovirus as human immunodeficiency virus (HIV) and confirmed HIV as the
causal agent associated with the development of AIDS. 10 HIV-1, a retrovirus, is
related to a family of lentiviruses that generally cause chronic, indolent
infections characterized by a long clinical latency period, nervous system
involvement, and persistent viremia. 11

CHAPTER III
BIOLOGY
Pathogenesis
The cellular events and reactions of HIV infection have become clearer
and have been discussed by a number of authorities in the United States. 12-14
The causative agent of HIV is now known to be one of the human retrovirus
that selectively infects CD4 lymphocytes and monocyte/macrophages. 15 The
structure, genetic composition, and major proteins of HIV have been identified,
and its basic pathophysiology defined. This chapter will cover the more
important features of the pathologic mechanisms occurring in the development
of the HIV disease.
Viruses are packets of infectious nucleic acid surrounded by protective
coats. In a virion, the viral nucleic acid is covered by a protein capsid, which
protects it from enzymatic attack and mechanical breakage and delivers it to a
susceptible host. 16 The capsid itself is surrounded by an envelope containing
membrane lipids and glycoproteins. The HIV virion (Figure 1) is enveloped by a
lipid bilayer membrane containing two glycoproteins: gp41 and gp120. 16-18 The
external envelope protein (gp120) is associated with small protrusions or spikes
on the outer surface of the virion and is attached to the viral capsid via
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Figure 1. Structure and genetic composition of HIV. (Courtesy of Jon Fuller, MD, Boston City
Hospital)
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the transmembrane protein, gp41. 19 The glycoprotein gp41 spans the
membrane and is disulfide-bonded to gp120, which is located on the external
face. 16-19
Retroviruses are enveloped and possess a single strand of ribonucleic
acid (RNA).20 All are characterized by their ability to serve as a template for
production of deoxyribonucleic acid (DNA) in host target celis. 16,18,19 This
reverse transcription is accomplished through possession of an enzyme.
Reverse transcriptase, a DNA polymerase, translates a single strand of RNA
into a double-stranded DNA copy.16,18-20 An additional viral enzyme, an
endonuclease, incorporates this DNA copy into the chromosomal structure of
the target cell as a provirus. 21
HIV Structure and Genetic Composition
HIV is composed of a central cylindrical core of diploid (two
chromosomes) RNA surrounded by a spherical lipid envelope. 22 The viral
genome (DNA and RNA) consists of three structural components: pol, gag, and
env (Figure 1) which are essential for productive infection. 18,23.24 The gag gene
(proteins) make up the core and the phosphoproteins that are found inside the
nucleoid. The protein gag codes for p24, which is found in the core and
surrounds the viral RNA. Gag or p24 also codes for other proteins, including
p17, p9, and p7.16.19.21 p24 is measurable in the serum and serves as a marker
for viral replication. 16 ,19.21 Pol codes for the reverse transcriptase (RNA-directed
DNA polymerase), which is responsible for the production of both the DNA
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polymerase and endonuclease located in the viral core. 16.21 The env gene
products include two glycoproteins that are part of the viral envelope: gp120
and gp41. Both proteins appear to be important for the recognition and
attachment of HIV to its CD4 lymphocyte target cel1. 24,25 These genes are
located between long terminal repeat (Itr) segments. LTRs carry multiple
signals--enhancers, promoters, and polyadenlylation sites--for the expression of
retroviral genes. 16
HIV also possesses genes that code for proteins having important
regulatory functions. 24 ,26 The tat (transactivator) gene is responsible for
production of a protein that enhances viral replication through its interaction with
long terminal repeats at either end of the genome. Rev (regulator of
expression) of virion proteins codes for the mechanism that results in the
discontinuation of regulatory protein production and increased production of
structural proteins. Vif (virion infectivity factor) codes for a protein that appears
important for the budding of viral progeny from the surface of the host cells and
their subsequent infectivity.
Pathophysiology of HIV Infection
The pathophysiology of HIV relates to its ability to infect human cells that
possess CD4 membrane receptors. The host cell for HIV is the T4 lymphocyte,
a vital contributor to the immune response; this lymphocyte was named for an
antigen present on its surface. Major target cells include monocytes,
macrophages, and their hematologic precursors. 27 Other cell types, including
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Langerhan's cells of the skin, epithelial gut cells, and uterine cervical cells, have
also been identified as harboring HIV infection. 21
CD4 receptors have a binding site capable of interacting with two
envelope proteins that are a part of the viral envelope. These include gp41 , the
transmembrane protein, and gp120 which protrudes from the envelope (Figure
2) and is closely associated with but not covalently linked to gp41. 18,22 Through
this proposed mechanism for HIV infection of a cell, the outside viral envelope
protein, gp120, attaches to a cell surface receptor, most likely the CD4 antigen.
The external portion of the transmembrane protein, gp41, attaches to a
proposed specific fusion receptor on the cell surface. Either receptor may
permit viral entry into the cell, but both together would make this event more
efficient. 16,21 Once the virus is within the cytoplasm of the host cell, the
envelope of the virus is shed, and its contents are released. 16,21 It is then that
reverse transcription occurs: a double-stranded DNA is made from the viral
RNA template. Newly created viral DNA can exist in either free form or it can
be integrated through the action of an endonuclease and go into the cellular
DNA as a provirus. 21 ,28
Infected cells remain in a dormant state for a variable period of time and
thus elude the host immune system possibly for years, a potential reason for
long incubation periods. 27,28 When activations occur, the proviral DNA
transcribes genomic and messenger RNA, leading to release of infectious
progeny.21,29 After viral proteins are synthesized, new virions are assembled
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that bud from the infected cell and circulate until they identify new target
cells. 21 ,29 These infected cells can then spread the virus through production of
infectious progeny or by fusion with uninfected cells. 30 This latter cell-to-cell
interaction is important because it permits the transfer of viral information into
an uninfected cell and avoids exposure of the newly formed viruses to
neutralizing antibodies. 21 ,28,29
The initial studies of the AIDS virus revealed its presence in peripheral
blood cells, particularly T-helper lymphocytes. 31 -33 Subsequently, HIV was
recovered from macrophages and was shown to infect a variety of other human
cells, including B lymphocytes, promyelocytes, fibroblast, and epidermal
Langerhans cells. 34-37 Therefore, the presence of the CD4 receptor appears to
explain the susceptibility of many cells to HIV. Monocytes and macrophages
serve an important role in the pathogenesis of HIV infection. 38 Once infected,
they appear to be tolerant of viral replication, surviving to disseminate virus to a
variety of body sites. Thus, these cells serve as an important source of
immunologically protected new virus. 21 It is generally accepted that monocyte
and macrophage function appears to be compromised to some degree by HIV
infection, contributing further to immunosuppression.
HIV affects the central nervous system (CNS) in a complex and
incompletely understood manner. It is thought that the HIV infected
macrophages probably carry the virus into the CNS across the blood-brain
barrier (Figure 3) by means of a "Trojan Horse" mechanism. 18,21 ,39 Once the
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virus gains access to the CNS, neurologic damage is likely to occur through
several different mechanisms. 21 Although HIV does not directly infect neurons
(Figure 4), infected macrophages may release toxic cytokines that are injurious
to neurons "innocent bystander mechanism.,,18,21,40 In addition, freely circulating
gp120 may result in neuronal damage by affecting the integrity of the blood
vessels supplying the nutrition or by interfering with normal calcium channel
function. 18,21,28,38,39
Response to HIV Infection and Stages of Infection
HIV infection elicits both cell-mediated and humoral immune responses
from the host. 41 Soon after infection with HIV, there is a brief period of intense
viral replication. During this time the patient is asymptomatic, but serologic
testing reveals a rise in titer of p24 antigen during the humoral response. 21 The
majority of individuals notice very few, if any, symptoms associated with
seroconversion. An estimated 40% to 60% of individuals will develop
symptoms of an acute mononucleosis-like syndrome, consisting of sore throat,
headache, fever, myalgias, lymphadenopathy, and skin rash. 42-44
The cellular immune response involves a decrease in absolute numbers
of CD4 lymphocytes with increase duration of infection. 45 This drop is usually
gradual for a prolonged period (clinical latency phase), with a more rapid
decline associated with the onset of symptoms later in the course of the
disease. The COB lymphocyte count generally increases early in HIV infection,
and together with macrophages may act in concert to interfere with viral
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replication by production of a diffusible factor or by directly killing infected
cells. 18,21,39,40 However, HIV infection is a chronic disease and in the end-stage
both CD4 and CD8 cell lines become depleted. The loss of CD4 lymphocyte
cells are associated with the development of the characteristic opportunistic
infections and malignancies of AIDS. Thus the measurement of CD4-positive
lymphocytes is one of the most important determinants for clinically staging the
disease status of HIV-infected patients. The absolute CD4 count cannot be
measured directly but is calculated by the following formula: 28
Absolute
CD4
Count

=

Total
Percent
Percent
White Blood X Lymphocytes X CD4
Count
Cells

Normal values for CD4 counts are generally 800 to 1200 cells/mm 3 in adults,
with fluctuations of as much as a 150 to 300 cell/mm 3 difference between
morning and evening values in normal adult hosts. 28 ,46 Asymptomaticlymphadenopathy may occur when the CD4 count drops below 800 cells/mm3.
When the CD4 cell count drops below 500 cells/mm 3, prophylaxis therapy is
recommended in response to immune dysfunction and/or to secondary
infections caused by opportunistic infections. 46
HIV is characterized by evolving clinical and serological manifestations
identified as predictors of HIV disease progression and the rate at which AIDS
develops. The clinical manifestations usually depend on the stage of infection.
Whether it is early infection with little immune dysfunction, or whether the
infection has been present long enough to cause moderate or severe immune
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impairment, HIV is a slowly progressive disease. A classification system for
these stages has been developed by the Center for Disease Control (Table 1).47
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Table 1. CDC Classification of HIV Infection.

Group
Group
Group
Group

1.
2.
3.
4.

Initial infection.
Asymptomatic carriers.
Persistent generalized adenopathy.
AIDS and AIDS-related complex
Subgroup 4A.
Constitutional symptoms
Subgroup 48.
Neurologic disease
Subgroup 4C.
Secondary infectious disease
Category 1 and 2
Various opportunistic infections
Subgroup 4D.
Secondary malignancies
Subgroup 4E.
Other AIDS-related conditions

National Institute of Mental Health, 1991.

CHAPTER IV
FUNCTIONAL AND CLINICAL MANIFESTATIONS
The immune system is complex, with many types of defenses against
infections. Understanding the effects of the HIV virus on the human immune
system is the key to understanding the clinical problems of HIV patients. HIV
infection is a highly lethal condition, with an average length of time from initial
infection to development of AIDS of approximately 10 years and a survival time
from the diagnosis of AIDS to death of approximately two to five years.48,49 HIV
is also known as a chronic disease with a fairly predictable pattern of evolution
and clinical manifestations. A physical therapist may treat a person with
HIV/AIDS who has several related conditions or opportunistic diseases. When
the person with AIDS develops secondary neurologic, musculoskeletal, or
cardiopulmonary complications the therapist provides physical therapy
evaluation and treatment. It is important that the physical therapist obtains
baseline data about the patient's state of being, state of fitness, and general
strength. Table 2 is a summary of the common HIV signs and symptoms, and
their possible causes of the HIV disease are presented. 21 ,28,46
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Table 2. Common Manifestations of HIV Disease
Signs and Symptoms

Possible Causes

SYSTEMIC
Weight loss

AIDS-related wasting syndrome, enteropathy,
depression

Tiredness

Wasting syndrome, anemia, opportunistic
infection

Fever and
night sweats

Primary HIV infection, TB, MAl, lymphoma

DERMATOLOGIC
Discoloration

Kaposi's sarcoma, tinea corporis, basal cell
carcinoma

Rash

Herpes zoster or simplex, psoriasis,
molluscum contagiosum, pustular
folliculitis, seborrhea, impetigo, drug
reaction

ORAL
White patches

Oral candidiasis, hairy leukoplakia, Herpes
simplex, cytomegalovirus, Kaposi'
sarcoma, aphthous ulcers

VISUAL
Visual field
optic

CMV or toxoplasma retinitis, syphilitic
defects neuritis, progress multifocal
leukoencephalopathy (PML)

FUNDOSCOPIC
Retinal hemorrhage

CMV retinitis

Retinal infiltrates

Benign HIV disease, CMV, toxoplasma
retinitis
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Table 2 (cont.) Common Manifestations of HIV Disease
Signs and Symptoms

Possible Causes

LYMPH NODES
Lymphadenopathy

AIDS-related lymphadenopathy, TB, KS
syphilis, lymphoma, bacterial or viral
infection

CARDIOPULMONARY
Cough, dyspnea,
SOB, tachypnea

Pneumocystis pneumonia, TB, bacterial
fungal, or viral pneumonia,
myocarditis, cardiomyopathy

HEMATOLOGIC
Easy bruisi ng,
bleeding

Idiopathic thrombocytopenic purura,
drug reaction, Kaposi's sarcoma

GASTROINTESTINAL
Diarrhea

Bacterial or parasitic infection, CMV, KS,
HIV-related enteropathy, food intolerance

Organomegaly

Lymphoma, TB, tumor, fungal infection
(histoplasmosis), MAl

Anal pain or ulcer

HSV, sarcoma, CMV, Abscess

GENITOURINARY
Genital lesions

Primary syphilis, HSV, chancroid, psoriasis,
papillomavirus

NEUROLOGIC
Headache

CNS toxoplasmosis, lymphoma, TB
meningitis or cryptococcal, PML
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Table 2 (cont.) Common Manifestations of HIV Disease
Signs and Symptoms

Possible Causes

Memory or thought
deficits

AIDS encephalopathy, meningitis, PML,
metabolic abnormalities, other organic
disorders

Nu mbness/dysesthesia

Herpes Zoster, neuropathy, myelopathy

Ataxia

CNS toxoplasmosis, lymphoma, PML,
syphilis, neuropathy, visual defect

Seizures

CNS toxoplasmosis, PML, CNS lymphoma,
meningitis, encephalitis
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Indicators of HIV Infection
In response to a growing awareness of the many manifestations of HIV
infection, the CDC has changed the definition of AIDS to include
encephalopathy, wasting syndrome, a CD4 count <200 cells/mm 3 , invasive
cervical cancer, recurrent pneumonia, and pulmonary tuberculosis. 46 ,5o
Neuropsychiatric Aspects of HIV Infection
The neuropsychiatric aspects of HIV infection present challenges for all
health-care workers. HIV infects the body and brain, and it always affects the
mind. Physical therapists will be increasingly faced with interpreting and
integrating the impact of HIV on a person's central nervous system function.
This section presents the neuropsychiatric manifestations of HIV-related
disorders that are relevant to physical therapy treatment concerns. Many of the
functional and organically based CNS disorders often affect the mental
capacity, the quality of life, and the maintenance of autonomous function and
independent living.
Many HIV-infected patients will have "mental symptoms" before they
develop the better known opportunistic infections. Patients may complain early
on of forgetfulness, mental slowing, social withdrawal, avoidance of complex
tasks, and personality changes. 51 Inattentiveness, inability to concentrate,
distractibility, and apathy may be subtle, and HIV patients may have
accommodated slowly to changes without realizing it. 51
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Dementia (subacute encephalitis, neurocognitive syndrome) is defined as
a complex of cognitive, motor, behavioral and affective abnormalities.
Impairment in some or all of these four categories of function may be present at
any time during the course of HIV disease. 52 ,53 People with HIV-infection may
continue to have these mild deficits, which are differentially disabling depending
on the patient's work or living situation, for long periods, without necessarily
progressing to further impairment. 54 Others progress fairly rapidly from these
signs to more disabling motor brain dysfunctions such as dysgraphia,
dysarthria, hyperreflexia, spasticity, incontinence, ataxia, mutism, aphasia,
myoclonus and seizures. 54 What is especially alarming to patients with HIVrelated neurocognitive decline is that unlike the patient with Alzheimer's
disease, the HIV person will retain intellectual function and consciousness of
the self until quite late in the disease process. 54
Delirium is reported as one of the most common psychiatric diagnoses
among hospitalized, severely ill AIDS patients. 55 Delirium in the HIV-infected
patient may result from secondary opportunistic infections and neoplasms. 54
Delirium is defined by DSM-IIIR with the general criteria as rambling, irrelevant,
or incoherent speech; illusions, hallucinations, disorientation to time, place, or
person; and reduced ability to maintain attention to external stimuli.

56

Organic mood disorders are expressed commonly as grandiose ideation,
delusions, mood swings, irritability, and personality changes. These symptoms
are pathologic changes in the limbic system that may be caused by HIV

24
infection. 57 •58 Adjustment disorders in HIV patients most common are anxiety
and depression. Studies suggest that a depressive syndrome may be the
precursor for the onset of a CNS infection and considered a reaction to HIV
illness. 59 •6o
Fatigue may be the presenting complaint of an underlying depression
early in the course of HIV infection. In later stages of HIV infection, fatigue may
be the result of chronic disease and is often perceived as untreatable. 54 .57 As
physical therapists, helping patients to learn about their energy levels and
proportioning their energy according to tasks is essential.
Because the HIV epidemic is still relatively new, only a few related
disability studies exist in the literature. Common problems among patients who
were referred consecutively to a rehabilitation service included generalized
deconditioning (27%) and neurologic dysfunction (45%)? Functional problems
included impaired mobility (76%), difficulty with self-care (57%), impaired
cognition (29%), and uncontrolled pain (37%)?
A more specific study documented the types and degrees of disability
found in persons with AIDS at discharge from acute care hospitalization, based
on the Functional Independence Measure (FIM).62 The FIM was developed by
the State University of New York, that covers 18 functional areas in self care,
mobility, communication, and social cognition; eating; grooming; bathing;
dressing (upper body); dressing (lower body); toileting, bladder management;
bowel management; bed, chair, and wheelchair transfer; toilet transfer; tub or
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shower transfer or both; walking or wheelchair locomotion; stair climbing;
comprehension; expression; social interaction; problem solving; and memory.63
Of the sample population, at least 60% required human assistance in one of the
18 functional areas; 32% in five or more areas. 63 Approximately 51 % required

human assistance in stair climbing; 38% in ambulation; 33% in eating and
bathing; and 25% in transferring to the bathtub or shower. 63 These daily living
skills were further compounded by the loss of self-esteem, loss of community,
and often differentiation pain resulting from partial or complete damage to
afferent nerve pathways toward the central nervous system. 63 ,64
Neurological Complications of HIV Infection
Although the loss of active daily living skills, psychiatric disorders, loss of
physical independence, and other problems are experienced, the most
significant disability faced by patients with HIV may be pain. The type of pain
depends on the disease process that is secondary to the HIV infection.
Potential etiologies of pain among patients with HIV include a wide variety of
rheumatologic, dermatologic, and musculoskeletal changes resulting from HIVrelated myopathy and muscle wasting syndrome. 63 ,65
The etiologies of pain consists of chest pain related to pneumocystis
carinii pneumonia (PCP); abdominal pain from (HIV-related lymphadenopathy,
Kaposi's sarcoma, infectious diarrhea, organomegaly, ileus, and nonspecific
gastritis); headache pain due to toxoplasmosis, CNS lymphoma, cryptococcus
meningitis; midsternal burning or dysphagia from herpes simplex,
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cytomegalovirus, candidiasis, infection; and low back pain may result from
malignant lymphomas. 63 ,65-67 These neurologic complications may evolve
acutely, during the asymptomatic phase, or during late nervous system
involvement by the HIV infection.
Additional neurological complications in the 200 to 500 CD4 cell/mm 3
count may result in meningitis, ataxia, myelopathy, cranial neuropathy (CN V,
VII, VIII), and brachial plexopathy.68 During the latent phase of HIV infection a
demyelinating neuropathy that resembles Guillain-Barre' syndrome and a
multiple sclerosis-like illness have been reported. 69-71
It has been estimated that up to 80% of all persons with HIV will have
some type of CNS or peripheral nervous system (PNS) involvement prior to
death.72 PNS dysfunction among patients with HIV may have multiple etiologies
in addition to the HIV infection itself, including malnutrition, immobility,
opportunistic infections, wasting syndrome, and drug toxicities.
Distal symmetric polyneuropathy (DSPN) is one of the most common
forms of neuropathy in patients with AIDS. DSPN may be described as a
progressive, painful neuropathy with prominent dysesthesia and areflexia with or
without mild muscle weakness. 73 Dysesthesias may be burning and constant.
The patient may report numbness or tingling in the toes that spread proximally;
later there may be finger and upper extremity involvement. 54 ,57,66,73 Tropic
changes may occur in distal areas of the skin, and muscle weakness varies;
generally it is mild, affecting the intrinsic foot muscles. 54 ,57,64,73 Distal reflexes
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are hypoactive or absent but may be present at the knees or in the upper
extremities. 54 ,64,73 Sensory dysfunction is usually moderately impaired. 54 ,64,73
Pathological studies suggest a retrograde process within the dorsal root ganglia
neurons and a degeneration of gracile tracts of spinal cord (mostly upper
thoracic or cervical cord segments).64
Chronic inflammatory demyelinating polyneuropathy (CIPD) is also a
consequence of HIV infection in the peripheral nervous system . This syndrome
is characterized by weakness in both proximal and distal muscles of the upper
and lower extremities. Reflexes may be sluggish or absent. 54 ,68 Finally, the
above symptoms of disease must be differentiated from medication side effects.
Zidovudine (formerly called azidothymidine, or AlT), and dideoxyinosine
(DOlor ddi) are commonly used antiviral drugs that inhibit the replication of
retroviruses, including HIV.72 The most common candidates for drug therapy
are patients with asymptomatic and symptomatic HIV infection who have a C04
cell count <500 cells/mm 3 •74 ,75 Side effects from AZT may include: headaches,
insomnia, nausea, vomiting, abdominal discomfort, diarrhea, malaise, myalgia,
rash, fever, and severe anemia. 54 ,65,75 001, typically prescribed for patients who
cannot tolerate AlT, has some of the same side effects; it may also cause
sensory peripheral neuropathy in the feet and pancreatitis symptoms. 54 ,65,75

CHAPTER V
SUBJECTIVE AND OBJECTIVE FINDINGS
Despite a decade of progress in understanding the molecular virology
and pathophysiology of the human immunodeficiency virus, the disease caused
by infection with this retrovirus remains incurable. As increasing numbers of
individuals have taken heed and have determined that they are, in fact, infected
with the retrovirus, they remain baffled by the lack of effective therapies. 76
The physical therapist faces multiple challenges when providing care to
this population. Of particular concern to physical therapists are the
neurological, psychological, musculoskeletal, cardiovascular, cardiopulmonary,
and nutritional effects of the disease. It is, at times, difficult to correlate specific
clinical signs of the disease with specific pathology because HIV has an impact
on all systems at variable rates of progression. This places the physical
therapist squarely in the health arena and PTs may be the first care provider to
see indications of HIV infection.
Good patient care requires that the diagnosis of HIV infection be made
at the earliest possible time. As with any patient, treatment should be based on
an accurate and appropriate assessment of the symptoms and on the patient's
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past and present medical history. The choice of treatment rests in the HIV
knowledge base and in the manifestation and interpretation of symptoms.
Even without evidence of gross clinical neurological symptoms or signs,
a physical therapist should have a basic understanding of the immune system
to recognize manifestations of the HIV disease. Pertinent information may be
gathered during the SUBJECTIVE and OBJECTIVE phases of the evaluation.
During the subjective information gathering client history may reveal
symptoms of unexplained weight loss, persistent diarrhea, night sweats,
recurrent fever, swollen glands, decreasing vision with eye pain, bleeding gums,
mouth sores, pain on swallowing, recent onset of headaches, easy tiring, and
irritability. There may be a loss of interest in friends and unusual activity.77-oo
Physical signs that may be directly observed by the therapist doing an
objective evaluation include severe dandruff and acne, skin rashes, purplish
spots, facial warts, ill-fitting clothes from weight loss, increased tone, unsteady
gait. Manifestations of infections that may coexist with HIV infections are
herpes (weeping skin lesions), hepatitis B (nausea and yellow eyes),
tuberculosis (productive cough, night sweats, and weight loss), and shingles
(angry painful rash).77-00
Effects on the musculoskeletal system not previously stated in this paper
may include an array of pain syndromes, postural deficits, and decreases in
work function capacity related to progressive weight loss and resultant fatigue. 81
Even when symptoms are lacking, motor abnormalities can almost always be

30
detected early in the course of the disease. Motor abnormalities include
slowing of rapid successive and alternating movements of the extremities,
impaired ocular smooth pursuits, and saccadic eye movements. 68 Abnormal
reflexes may also be present, with generalized hyperreflexia and the
development of release signs such as snout, glabellar, and grasp
responses. 68 ,80,82,83 As the disease evolves, ataxia and, subsequently, leg
weakness limits walking. Bladder and bowel incontinence is common in the late
stages of the disease. 68 ,77,78,80,82,83
In addition to obtaining musculoskeletal and neurological subjective and
objective data, a physical therapist must also be concerned with the
cardiovascular, pulmonary, and nutritional systems and the psychological
implications for patients with HIV. These systems have ever changing variables
that depend on the type of opportunistic infection(s) involved, the adequacy of
nutrition, the level of pain, and the level of cognitive functioning. 84 Further
discussion of these systems concerning medical aspects of HIV infection is
beyond the scope of this independent study.

CHAPTER VI
CONCLUSION
Acquired Immunodeficiency Syndrome is now an epidemic in the United
States, and all sectors of society are being affected. The care of HIV/AIDS
infected patients is demanding. Thus, raising concerns among health care
workers about safety, competence, and care requires both high-quantity and
high-quality of time to treat this special population. As physical therapists we
are in key positions to identify and intervene in the changes and losses
commonly experienced by this unique disease.
The physical therapist is an important contributor at all stages of the
disease. When the person with HIV develops neurologic, musculoskeletal, or
cardiopulmonary complications as a result of AIDS, The PT provides baseline
data about the patient's state of fitness and function through evaluations and
treatments. Therefore, physical therapists have the opportunity to apply their
therapeutic skills to improve function, mobility, endurance, and safety. They
can also communicate the importance of healthy living and physical fitness and
identify potential problems before they erode the patient's confidence and
independence. Physical therapy can be an effective method to help meet the
needs of this complex population.
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HIV has altered forever the ways in which we think about and act on life
and living. Therefore, a solid understanding of HIV pathogenesis and a general
working knowledge of signs and symptoms of HIV/AIDS are indispensable. As
physical therapists we face multiple challenges when providing care to patients
with HIV disease. There is a clearly articulated responsibility to take action to
strengthen our personal and professional character, values, and integrity.
Furthermore, we need to become role models in health care and participate in
the forming of the future -- namely to "influence our professional evolution
through our own awareness." The final and most obvious reason for physical
therapists to become more involved in HIV/AIDS health care is the clear need
of all patients for expert, comprehensive, and efficient care.
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